INS and metabolic disease: In this patent are thiazolidinedione derivatives of omega-3 fatty acids as insulin sensitizers, and use in the treatment of type 2 diabetes, CVD, renal anemia, Alzheimer’s disease, hypertriglyceridemia, obesity, metabolic diseases, and modulating activity of peroxisome proliferator-activated receptors (PPARs).